Oral metabolic adjunct research combines early clinical and animal studies assessing its use alongside weekly incretin therapy, offering insight into weight and metabolic implications.
Key Takeaways
- Randomized double-blind placebo-controlled study lasted 24 weeks
- Adding oral TLC-6740 to weekly tirzepatide increased mean weight loss by 4.5%
- Mitochondrial protonophore candidate improved energy expenditure and insulin sensitivity in obese mice